C-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT

Oncogene

Volumn 34, Issue 16, 2014, Pages 2072-2082

  Wu, D W ^a   Hsu, N Y ^a   Wang, Y C ^b,c   Lee, M C ^d   Cheng, Y W ^a   Chen, C Y ^e   Lee, H ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID ANHYDRIDE HYDROLASE; FRAGILE HISTIDINE TRIAD PROTEIN; MICRORNA; MIRN29 MICRORNA, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; TUMOR PROTEIN;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; DISEASE FREE SURVIVAL; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION; TUMOR RECURRENCE;

ACID ANHYDRIDE HYDROLASES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE-FREE SURVIVAL; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION;

EID: 84938934841     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.152     Document Type: Article

References (41)

1. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-845.
2. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810.
3. Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol 2011; 224: 484-495.
4. Yu PN, Yan MD, Lai HC, Huang RL, Chou YC, Lin WC et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer 2013; 134: 542-551.
5. Rothschild SI, Tschan MP, Federzoni EA, Jaggi R, Fey MF, Gugger M et al. MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene 2012; 31: 4221-4232.
6. Plaisier CL, Pan M, Baliga NS. A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res 2012; 22: 2302-2314.
7. Gebeshuber Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011; 30: 4750-4756.
8. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009; 10: 400-405.
9. Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS ONE 2011; 6: E19518.
10. Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol 2013; 754: 3-29.
11. Lee YC, Wu CT, Shih JY, Jou YS, Chang YL. Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers. Br J Cancer 2004; 90: 2378-2383.
12. Kim JS, Kim H, Shim YM, Han J, Park J, Kim DH. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 2004; 25: 2165-2171.
13. Wang J, Cheng YW, Wu DW, Chen JT, Chen CY, Chou MC et al. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan. Cancer Lett 2006; 235: 18-25.
14. Yoon SO. Abnormal fragile histidine triad (Fhit) expression in invasive cervical adenocarcinoma: Association with tumor aggressiveness. Hum Pathol 2007; 38: 326-331.
15. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV et al. Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 2000; 6: 3505-3510.
16. Butler D, Collins C, Mabruk M, Barry Walsh C, Leader MB, Kay EW. Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features. J Pathol 2000; 192: 502-510.
17. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.
18. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 2010; 110: 1155-1164.
19. Gong JN, Yu J, Lin HS, Zhang XH, Yin XL, Xiao Z et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ 2014; 21: 100-112.
20. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012; 22: 506-523.
21. McMurray HR, McCance DJ. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. J Virol 2003; 77: 9852-9861.
22. Xu M, Katzenellenbogen RA, Grandori C, Galloway DA. NFX1 plays a role in human papillomavirus type 16 E6 activation of NFkappaB activity. J Virol 2010; 84: 11461-11469.
23. James MA, Lee JH, Klingelhutz AJ. Human papillomavirus type 16 E6 activates NFkappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol 2006; 80: 5301-5307.
24. Pylkkanen L, Wolff H, Stjernvall T, Tuominen P, Sioris T, Karjalainen A et al. Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients. Int J Oncol 2002; 20: 285-290.
25. Burke L, Khan MA, Freedman AN, Gemma A, Rusin M, Guinee DG et al. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 1998; 58: 2533-2536.
26. Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 2004; 100: 1472-1477.
27. Pavelic K, Krizanac S, Cacev T, Hadzija MP, Radosevic S, Crnic I et al. Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas. Mol Med 2001; 7: 442-453.
28. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998; 58: 5478-5483.
29. Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999; 59: 4798-4803.
30. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006; 66: 4049-4054.
31. Wu DW, Tsai LH, Chen PM, Lee MC, Wang L, Chen CY et al. Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer. Am J Pathol 2012; 181: 1796-1806.
32. Wu MF, Cheng YW, Lai JC, Hsu MC, Chen JT, Liu WS et al. Frequent p16INK4a promoter hypermethylation in human papillomavirus-infected female lung cancer in Taiwan. Int J Cancer 2005; 113: 440-445.
33. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 2007; 67: 10686-10693.
34. Okuyama H, Endo H, Akashika T, Kato K, Inoue M. Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res 2010; 70: 10213-10223.
35. Jamerson MH, Johnson MD, Dickson RB. Dual regulation of proliferation and apoptosis: C-myc in bitransgenic murine mammary tumor models. Oncogene 2000; 19: 1065-1071.
36. Napoli C, Lerman LO, de Nigris F, Sica V. c-Myc oncoprotein: A dual pathogenic role in neoplasia and cardiovascular diseases? Neoplasia 2002; 4: 185-190.
37. Robson S, Pelengaris S, Khan M. c-Myc and downstream targets in the pathogenesis and treatment of cancer. Recent Pat Anticancer Drug Discov 2006; 1: 305-326.
38. Wolfer A, Ramaswamy S. MYC and metastasis. Cancer Res 2011; 71: 2034-2037.
39. Wu DW, Cheng YW, Wang J, Chen CY, Lee H. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res 2010; 70: 10392-10401.
40. Kristensen LS, Mikeska T, Krypuy M, Dobrovic A. Sensitive meltings analysis after real time-methylation specific pcr (smart-msp): High-throughput and probe-free quantitative dna methylation detection. Nucleic Acids Res 2008; 36: E42.
41. Treppendahl MB, Qiu X, Sogaard A, Yang X, Nandrup-Bus C, Hother C et al. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood 2012; 119: 206-216.